The use of myo-inositol in the treatment of female infertility in assisted reproductive technology programs in patients at high risk for immature gametes
- Authors: Vladimirova I.V1, Donnikov A.E1, Makarova N.P1, Kalinina E.A1
-
Affiliations:
- Research Center of Obstetrics, Gynecology, and Perinatology
- Issue: No 7 (2017)
- Pages: 146-149
- Section: Articles
- URL: https://journals.eco-vector.com/0300-9092/article/view/248001
- DOI: https://doi.org/10.18565/aig.2017.7.146-9
- ID: 248001
Cite item
Open Access
Access granted
Abstract
Objective. To analyze the data available in the current literature on the effect of myo-inositol on the effectiveness of assisted reproductive technology (ART) programs and its role in the physiology of the female reproductive system. Material and methods. The article includes the data of foreign and Russian articles published in the past 5 years and found in Pubmed on this topic. Results. Possible mechanisms of myo-inositol involvement in oocyte maturation processes are described. The use of myo-inositol in the treatment of infertility in patients at high risk for obtaining immature germ cells (oocytes) can improve the quality of oocytes obtained during superovulation and increase the frequency of fertilization at the embryonic stage. Conclusion. In detecting a high risk of obtaining immature sex cells, the use of myo-inositol in IVF preparation programs can increase the chance of obtaining mature oocytes by providing a full meiotic, as well as reduce the hormonal load and increase the effectiveness of the procedure in general.
Full Text
About the authors
I. V Vladimirova
Research Center of Obstetrics, Gynecology, and Perinatology
Email: inteterina@yandex.ru
researcher of the Department of assistive reproductive technology in the treatment of infertility
A. E Donnikov
Research Center of Obstetrics, Gynecology, and Perinatology
Email: a_donnikov@oparina4.ru
PhD, senior researcher of laboratory of molecular genetic methods
N. P Makarova
Research Center of Obstetrics, Gynecology, and Perinatology
Email: np.makarova@gmail.com
M.D., Ph.D., Head of the Department of assistive reproductive technology in the treatment of infertility
E. A Kalinina
Research Center of Obstetrics, Gynecology, and Perinatology
Email: e_kalinina@oparina4.ru
M.D., Ph.D., Head of the Department of assistive reproductive technology in the treatment of infertility
References
- Pacchiarotti A., Selman H., Valeri C., Napoletano S., Sbracia M., Antonini G. et al. Ovarian stimulation protocol in IVF: An up-to-date review of the literature. Curr. Pharm. Biotechnol. 2016; 17(4): 303-15.
- Владимирова И.В., Калинина Е.А., Донников А.Е. Модель прогнозирования получения незрелых ооцитов в программах вспомогательных репродуктивных технологий с учетом генотипа пациенток. Акушерство и гинекология. 2016; 1: 63-7. http://dx.doi.org/10.18565/aig.2016.1.63-67 [Vladimirova I.V., Kalinina E.A., Donnikov A.E. A model for predicting the probability of obtaining immature oocytes in assisted reproductive technology programs with regard to the genotype of patients. Akusherstvo i ginekologiya/ Obstetrics and Gynecology. 2016; (1): 63-67. (in Russian) http://dx.doi. org/10.18565/aig.2016.1.63-67]
- Rago R., Marcucci I., Leto G., Caponecchia L., Salacone P., Bonanni P. et al. Effect of myo-inositol and alpha-lipoic acid on oocyte quality in polycystic ovary syndrome non-obese women undergoing in vitro fertilization: a pilot study. J. Biol. Regul. Homeost. Agents. 2015; 29(4): 913-23.
- Владимирова И.В., Калинина Е.А., Донников А.Е. Прогнозирование исходов программ вспомогательных репродуктивных технологий с использованием молекулярно-генетических маркеров. Гинекология. 2014; 16(6): 33-6. [Vladimirova I.V., Kalinina E.A., Donnikov A.E. Predicting the outcomes of programs of assisted reproductive technologies using molecular genetic markers. Ginekologiya. 2014; 16 (6): 33-6. (in Russian)]
- Громова О.А., Торшин И.Ю., Гришина Т.Р., Громов А.Н., Лиманова О.А. Систематический анализ молекулярно-физиологических эффектов миоинозитола: данные молекулярной биологии, экспериментальной и клинической медицины. Эффективная фармакотерапия. 2013; 23: 4-12. [Gromova O.A., Torshin I.Yu., Grishina T.R., Gromov A.N., Limanova O.A. A systematic analysis of the molecular-physiological effects of myoinositol: data from molecular biology, experimental and clinical medicine. Effektivnaya farmakoterapiya. 2013; 23: 4-12. (in Russian)]
- Venturella R., Mocciaro R., De Trana E., DAlessandro P., Morelli M., Zullo F. Assessment of the modification of the clinical, endocrinal and metabolical profile of patients with PCOS syndrome treated with myo-inositol. Minerva Ginecol. 2012; 64(3): 239-43.
- Turan G.A., Eskicioglu F., Sivrikoz O.N., Cengiz H., Adakan S., Gur E.B. et al. Erratum to: Myo-inositol is a promising treatment for the prevention of ovarian hyperstimulation syndrome (OHSS): an animal study. Arch. Gynecol. Obstet. 2016; 293(3): 691.
- Lisi F., Carfagna P., Oliva M.M., Rago R., Lisi R., Poverini R. et al. Pretreatment with myo-inositol in non polycystic ovary syndrome patients undergoing multiple follicular stimulation for IVF: a pilot study. Reprod. Biol. Endocrinol. 2012; 10: 52.
- Konieczny V., Stefanakis J.G., Sitsanidis E.D., Ioannidou N.A., Papadopoulos N.V., FylaktakidouK.C. et al. Synthesis of inositol phosphate-based competitive antagonists of inositol 1,4,5-trisphosphate receptors. Org. Biomol. Chem. 2016; 14(8): 2504-14.
Supplementary files
